Numab Therapeutics
PrivateLast Round
Series C
Extension
Jan 9, 2025
Est. Valuation
$1.25B
Total Funding Raised
$187.6M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Numab Therapeutics is a biotechnology company that develops multispecific antibody-based immunotherapies for the treatment of chronic inflammation and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Numab Therapeutics Comparables
Compare Numab Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Crescendo Biologics Ltd. | 84% | |
| EpimAb Biotherapeutics | 83% | |
| Adimab | 82% |
Numab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 9, 2025 | ||||
| M&A | Jul 11, 2024 | ||||
| Series C | May 20, 2021 | ||||
| Series B | Mar 9, 2020 |
Key People
Founding team and executive leadership
Numab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series C Extension |
| Octagon Capital Advisors | Series C Extension, Series C |
| Cormorant Asset Management | Series C, Series C Extension |
| Flerie Invest | Series C Extension, Series C |
| HBM Healthcare Investments | Series C Extension |
| Novo Holdings | Series C Extension, Series C |
| BVF Partners L.P. | Series C Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 121% MoM, reaching 4.1K.
- Sep 25, 2025
Achieved an unspecified milestone in collaboration with Boehringer Ingelheim.
Numab Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Numab Therapeutics's valuation, stock price, and market status.
Is Numab a public or private company?
Numab is a private company.
What is the current stock price of Numab?
Numab is a private company with no public stock price. No recent secondary market data is available.
How much is Numab worth (valuation)?
Valuation information for Numab is not publicly available.
Can I buy Numab stock?
Numab shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Numab's last funding round?
Numab's most recent funding round was Series C Extension on January 9, 2025.
Who are the main investors in Numab?
Key investors in Numab include Forbion, Novo Holdings, Cormorant Asset Management, HBM Partners.
Will Numab IPO soon?
No public IPO plans have been announced for Numab.
How can I track Numab secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Numab's secondary market activity and sign up for updates.